{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "Bevezet\u00e9s: A Clostridium difficile az antibiotikum-haszn\u00e1lattal \u00f6sszef\u00fcgg\u0151 hasmen\u00e9sek 25%-\u00e1t okozza. A Clostridium difficile-fert\u0151z\u00e9s priorit\u00e1sk\u00e9nt kezelt n\u00e9peg\u00e9szs\u00e9g\u00fcgyi probl\u00e9ma valamennyi orsz\u00e1gban. A fert\u0151z\u00e9s epidemiol\u00f3gi\u00e1j\u00e1r\u00f3l, betegs\u00e9gterh\u00e9r\u0151l viszonylag kev\u00e9s szakirodalmi adat \u00e1ll rendelkez\u00e9sre. C\u00e9lkit\u0171z\u00e9s: A Clostridium difficile-fert\u0151z\u00e9s epidemiol\u00f3gi\u00e1j\u00e1nak, ezen bel\u00fcl szezonalit\u00e1s\u00e1nak \u00e9s az egym\u00e1st k\u00f6vet\u0151 fert\u0151z\u00e9sek rizik\u00f3j\u00e1nak, valamint betegs\u00e9gterh\u00e9nek \u00e9s ter\u00e1pi\u00e1j\u00e1nak \u00e1ttekint\u00e9se. M\u00f3dszer: A nemzetk\u00f6zi \u00e9s hazai szakirodalom \u00e1ttekint\u00e9se a MEDLINE adatb\u00e1zisban a PubMed-en kereszt\u00fcl, 2012. m\u00e1rcius 20-\u00e1val bez\u00e1r\u00f3lag. Eredm\u00e9nyek: A nosocomialis Clostridium difficile-fert\u0151z\u00e9s incidenci\u00e1ja 4,1/10 000 \u00e1pol\u00e1si nap. A fert\u0151z\u00e9s szezonalit\u00e1s\u00e1nak k\u00e9rd\u00e9se felmer\u00fclt, de nem bizony\u00edtott. A betegek 20%-\u00e1ban fordul el\u0151 rekurrencia metronidazol- vagy vankomicinter\u00e1pia ut\u00e1n, minden egyes rekurrencia ut\u00e1n a k\u00f6vetkez\u0151 rekurrencia rizik\u00f3ja n\u00f6vekv\u0151. A CDI k\u00f6lts\u00e9ge haz\u00e1nkban 130\u2013500 ezer Ft/k\u00f3rh\u00e1zi eset. K\u00f6vetkeztet\u00e9sek: A Clostridium difficile-fert\u0151z\u00e9s n\u00e9peg\u00e9szs\u00e9g\u00fcgyi s\u00falya \u00e9s betegs\u00e9gterhe jelent\u0151s. Haz\u00e1nkban a rendelkez\u00e9sre \u00e1ll\u00f3 adatok korl\u00e1tozottak, mind az epidemiol\u00f3gia, mind az eg\u00e9szs\u00e9g-gazdas\u00e1gtan ter\u00e9n tov\u00e1bbi kutat\u00e1sok sz\u00fcks\u00e9gesek. Orv. Hetil., 2013, 154, 1188\u20131193."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "23876616",
  "DateCompleted": {
    "Year": "2013",
    "Month": "11",
    "Day": "08"
  },
  "DateRevised": {
    "Year": "2020",
    "Month": "12",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "hun"
    ],
    "ELocationID": [
      "10.1556/OH.2013.29674"
    ],
    "Journal": {
      "ISSN": "0030-6002",
      "JournalIssue": {
        "Volume": "154",
        "Issue": "30",
        "PubDate": {
          "Year": "2013",
          "Month": "Jul",
          "Day": "28"
        }
      },
      "Title": "Orvosi hetilap",
      "ISOAbbreviation": "Orv Hetil"
    },
    "ArticleTitle": "[Clostridium difficile infection: epidemiology, disease burden and therapy].",
    "Pagination": {
      "StartPage": "1188",
      "EndPage": "1193",
      "MedlinePgn": "1188-93"
    },
    "Abstract": {
      "AbstractText": [
        "C. difficile causes 25 percent of the antibiotic associated infectious nosocomial diarrhoeas. C. difficile infection is a high-priority problem of public health in each country. The available literature of C. difficile infection's epidemiology and disease burden is limited.",
        "Review of the epidemiology, including seasonality and the risk of recurrences, of the disease burden and of the therapy of C. difficile infection.",
        "Review of the international and Hungarian literature in MEDLINE database using PubMed up to and including 20th of March, 2012.",
        "The incidence of nosocomial C. difficile associated diarrhoea is 4.1/10 000 patient day. The seasonality of C. difficile infection is unproved. 20 percent of the patients have recurrence after metronidazole or vancomycin treatment, and each recurrence increases the chance of a further one. The cost of C. difficile infection is between 130 and 500 thousand HUF (430 \u20ac and 1665 \u20ac) in Hungary.",
        "The importance of C. difficile infection in public health and the associated disease burden are significant. The available data in Hungary are limited, further studies in epidemiology and health economics are required."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Budapesti Corvinus Egyetem, Eg\u00e9szs\u00e9g-gazdas\u00e1gtani \u00e9s Eg\u00e9szs\u00e9g\u00fcgyi Technol\u00f3giaelemz\u00e9si Kutat\u00f3k\u00f6zpont K\u00f6zszolg\u00e1lati Tansz\u00e9k Budapest."
          }
        ],
        "LastName": "Gul\u00e1csi",
        "ForeName": "L\u00e1szl\u00f3",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kert\u00e9sz",
        "ForeName": "Adrienne",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kopcs\u00f3n\u00e9 N\u00e9meth",
        "ForeName": "Ir\u00e9n",
        "Initials": "I"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Banai",
        "ForeName": "J\u00e1nos",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ludwig",
        "ForeName": "Endre",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Prinz",
        "ForeName": "Gyula",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Rem\u00e9nyi",
        "ForeName": "P\u00e9ter",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Strb\u00e1k",
        "ForeName": "B\u00e1lint",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Zsoldin\u00e9 Urb\u00e1n",
        "ForeName": "Edit",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Baji",
        "ForeName": "Petra",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "P\u00e9ntek",
        "ForeName": "M\u00e1rta",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Brodszky",
        "ForeName": "Valentin",
        "Initials": "V"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ],
    "VernacularTitle": "A Clostridium difficile-fert\u0151z\u00e9sek epidemiol\u00f3gi\u00e1ja, betegs\u00e9gterhe \u00e9s ter\u00e1pi\u00e1ja."
  },
  "MedlineJournalInfo": {
    "Country": "Hungary",
    "MedlineTA": "Orv Hetil",
    "NlmUniqueID": "0376412",
    "ISSNLinking": "0030-6002"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "140QMO216E",
      "NameOfSubstance": "Metronidazole"
    },
    {
      "RegistryNumber": "6Q205EH1VU",
      "NameOfSubstance": "Vancomycin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [
        "economics",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [
        "isolation & purification"
      ],
      "DescriptorName": "Clostridioides difficile"
    },
    {
      "QualifierName": [
        "drug therapy",
        "economics",
        "epidemiology"
      ],
      "DescriptorName": "Clostridium Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cost of Illness"
    },
    {
      "QualifierName": [
        "drug therapy",
        "economics",
        "epidemiology"
      ],
      "DescriptorName": "Cross Infection"
    },
    {
      "QualifierName": [
        "microbiology"
      ],
      "DescriptorName": "Diarrhea"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Costs"
    },
    {
      "QualifierName": [
        "drug therapy",
        "economics",
        "epidemiology"
      ],
      "DescriptorName": "Enterocolitis, Pseudomembranous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Health Care Costs"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Hungary"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Metronidazole"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Public Health"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Recurrence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Seasons"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Vancomycin"
    }
  ]
}